Evolus, INC 10-Q quarterly reports

Evolus, Inc. reported a 21.2% increase in net revenues for the three months ended June 30, 2026, driven by higher Jeuveau sales, while also addressing potential tariff impacts.

Evolus, Inc. announced its first-quarter 2026 financial results, reporting a 6.7% increase in net revenues to $73.1 million, driven by the launch of Evolysse and international growth of Jeuveau.

Evolus, Inc. reported increased net revenues in Q3 2025 driven by new product launches, but also saw a widening net loss and increased cash usage from operations.

Evolus, Inc. reported a wider net loss in the second quarter of 2025, driven by increased operating expenses and higher interest costs, despite the successful U.S. launch of its new Evolysse product line.

Evolus, Inc. announces its Q1 2025 financial results, highlighting a 15.5% increase in revenue compared to the same period last year, driven by higher sales volumes of Jeuveau.

Evolus, Inc. reports a 22.2% increase in net revenue for the third quarter of 2024, primarily driven by higher sales volumes of its flagship product, Jeuveau.

Evolus, Inc. reports a 35.7% increase in net revenue for the second quarter of 2024, driven by higher sales volumes of Jeuveau, and provides updates on its dermal filler development.

Evolus, Inc. announced a 42% increase in net revenue for the first quarter of 2024, driven by higher sales volumes of its flagship product, Jeuveau.